This is the authors' abstract. We don't add key points for this paper.
Background Immunoglobulin A nephropathy (IgAN) has a high incidence rate and a poor prognosis. Currently, no ideal treatment is available for this disease. Despite some reports on the use of telitacicept in IgAN, studies with a treatment duration of 24 weeks or longer remain limited, and data on its combination with glucocorticoids are currently lacking. Methods This retrospective cohort study enrolled 136 individuals diagnosed with IgAN via renal biopsy who exhibited 24-h urinary protein excretion (UPE) ≥ 1 g and an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m 2 . Of these, 25 received RAS inhibitors, 55 received glucocorticoid ± immunosuppressants, 18 received telitacicept, and 38 received telitacicept + glucocorticoids. Results At 24 weeks, compared with baseline, median UPE decreased by 0.70 g (41.75%) in the RAS inhibitor group, by 0.92 g (62.85%) in the glucocorticoid ± immunosuppressant group, by 1.14 g (73.68%) in the telitacicept group, and by 1.34 g (81.18%) in the telitacicept + glucocorticoid group. The reduction in UPE was significantly greater in the latter three groups than in the RAS inhibitor group (p < 0.05). Moreover, the telitacicept + glucocorticoid group demonstrated a significantly greater reduction in UPE than the other groups. The eGFR decreased by 3.22 ml/min/1.73 m 2 (−16.77, −0.70) in the RAS inhibitor group compared with baseline, whereas it remained stable in the other groups. Among patients with UPE ≥2.5 g or eGFR <60 ml/min/1.73 m 2 , the telitacicept + glucocorticoid group showed a significantly greater reduction in UPE than the other groups (p < 0.05). Conclusion These findings indicate that in IgAN patients with a high risk of progression, telitacicept effectively reduces proteinuria and confers kidney protective effects. Furthermore, in individuals with UPE ≥2.5 g or impaired renal function, the combination of telitacicept and glucocorticoids is associated with improved rates of UPE remission.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: